Adam Lerner, MD

Professor, Medicine

Adam Lerner
617.638.7504
650 Albany St Evans Biomed Research Ctr

Biography

Dr. Lerner is a Professor of Medicine, Pathology and Laboratory Medicine at Boston University School of Medicine (BUSM) and a medical oncologist at Boston Medical Center (BMC). He received his MD from Yale School of Medicine, followed by an internal medicine residency at Boston City Hospital. He did his fellowship in Medical Oncology at the Dana Farber Cancer Institute, Harvard Medical School, and subsequently remained there while carrying out research in the cellular and molecular biology of T lymphocytes. In 1996, he joined the Hematology/Oncology Section at Boston Medical Center. His laboratory research has focused in two areas: 1) The therapeutic potential of cyclic nucleotide phosphodiesterase inhibitors in lymphoid malignancies; 2) The mechanism by which a novel adapter protein (BCAR3/ AND-34) modulates focal adhesion complex signaling in mesenchymal, epithelial and hematopoietic cells. Clinically, Dr. Lerner cares for patients with hematologic malignancies, cutaneous malignancies and sarcomas.

Expertise includes: CLL; Leukemia; Lymphoid malignancies; Sarcoma; Breast cancer; cAMP signaling.

Other Positions

  • Professor, Pathology & Laboratory Medicine, Boston University School of Medicine
  • Member, BU-BMC Cancer Center, Boston University
  • Member, Evans Center for Interdisciplinary Biomedical Research, Boston University
  • Member, Genome Science Institute, Boston University
  • Graduate Faculty (Primary Mentor of Grad Students), Boston University School of Medicine, Graduate Medical Sciences

Education

  • Yale University School of Medicine, MD
  • Amherst College, AB

Classes Taught

  • GMSMM703

Publications

  • Published on 3/9/2022

    Hughes DM, Henshaw L, Blevins F, Edwards C, Lerner A, Sloan JM, Sanchorawala V. Standard 30-minute Monitoring Time and Less Intensive Pre-medications is Safe in Patients Treated With Subcutaneous Daratumumab for Multiple Myeloma and Light Chain Amyloidosis. Clin Lymphoma Myeloma Leuk. 2022 Mar 09. PMID: 35367193.

    Read at: PubMed
  • Published on 2/25/2022

    Milrod CJ, Mann M, Blevins F, Hughes D, Patel P, Li KY, Lerner A, Sanchorawala V, Sloan JM. Underrepresentation of Black participants and adverse events in clinical trials of lenalidomide for myeloma. Crit Rev Oncol Hematol. 2022 Apr; 172:103644. PMID: 35227897.

    Read at: PubMed
  • Published on 5/27/2021

    Milrod CJ, Blevins F, Hughes D, Lerner A, Sarosiek S, Sanchorawala V, Sloan JM. Incidence of skin hyperpigmentation in Black patients receiving treatment with immunomodulatory drugs. Blood. 2021 05 27; 137(21):2987-2989. PMID: 33728443.

    Read at: PubMed
  • Published on 9/8/2020

    Prilutskiy A, Kritselis M, Shevtsov A, Yambayev I, Vadlamudi C, Zhao Q, Kataria Y, Sarosiek SR, Lerner A, Sloan JM, Quillen K, Burks EJ. SARS-CoV-2 Infection-Associated Hemophagocytic Lymphohistiocytosis. Am J Clin Pathol. 2020 09 08; 154(4):466-474. PMID: 32681166.

    Read at: PubMed
  • Published on 5/27/2020

    Dennis M, Maoz A, Cirstea D, Patel A, Lerner A, Sarosiek S. Treatment disparities in minority groups with multiple myeloma at a safety-net hospital. Leuk Lymphoma. 2020 10; 61(10):2507-2510. PMID: 32460648.

    Read at: PubMed
  • Published on 1/31/2019

    Leiva O, McMahon L, Sloan JM, Lee J, Lerner A. Recognition of hemophagocytic lymphohistiocytosis in sickle cell vaso-occlusive crises is a potentially lifesaving diagnosis. Haematologica. 2019 04; 104(4):e167-e169. PMID: 30705096.

    Read at: PubMed
  • Published on 1/15/2018

    Min MS, Al-Haseni A, Succaria F, Goldberg L, Lerner A, Sahni D. Anaplastic large cell lymphoma localized to the left breast years after radiotherapy for breast cancer. Dermatol Online J. 2018 Jan 15; 24(1). PMID: 29469762.

    Read at: PubMed
  • Published on 9/1/2017

    de Medeiros AS, Wyman AR, Alaamery MA, Allain C, Ivey FD, Wang L, Le H, Morken JP, Habara A, Le C, Cui S, Lerner A, Hoffman CS. Identification and characterization of a potent and biologically-active PDE4/7 inhibitor via fission yeast-based assays. Cell Signal. 2017 Dec; 40:73-80. PMID: 28867658.

    Read at: PubMed
  • Published on 8/30/2017

    Duvic M, Bates SE, Piekarz R, Eisch R, Kim YH, Lerner A, Robak T, Samtsov A, Becker JC, McCulloch W, Waksman J, Whittaker S. Responses to romidepsin in patients with cutaneous T-cell lymphoma and prior treatment with systemic chemotherapy. Leuk Lymphoma. 2018 04; 59(4):880-887. PMID: 28853310.

    Read at: PubMed
  • Published on 8/10/2016

    Foss F, Duvic M, Lerner A, Waksman J, Whittaker S. Clinical Efficacy of Romidepsin in Tumor Stage and Folliculotropic Mycosis Fungoides. Clin Lymphoma Myeloma Leuk. 2016 Nov; 16(11):637-643. PMID: 27637428.

    Read at: PubMed

View 69 more publications: View full profile at BUMC

View all profiles